Pharmaceutical

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.

Jan 9, 2024 - 18:00
AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval
AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.
Read the original article

Tags:

Previous Article

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood o...

Next Article

Successful Phase 3 Trials Propel Innovent’s Mazdutide into China’s Obesity Market

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk and Aspect join forces for bioprinting tissue therapeutics

Novo Nordisk and Aspect join forces for bioprinting tis...

Apr 12, 2023

J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius

J&J signs Stelara biosimilar settlement deal with Formy...

Aug 8, 2023

Anavex Life Sciences receives US patent for ANAVEX 2-73 (blarcamesine)

Anavex Life Sciences receives US patent for ANAVEX 2-73...

Jun 3, 2023